OVERVIEW
Mesenteric fibrosarcoma is a malignant tumor derived from fibroblasts and collagen fibers. It can occur at any age, but is more common in young and middle-aged people, and is partly congenital. It tends to grow aggressively.
Etiology
The etiology and pathogenesis are still unclear, and are currently thought to be related to post-traumatic scar repair, various fistulas or sinus tracts, radiation exposure, and genetic factors.
Symptoms
Mesenteric fibrosarcoma has no obvious symptoms in the early stage, and symptoms do not appear until the tumor grows larger. The main manifestations are abdominal mass, abdominal distension, abdominal pain, low back pain, difficulty in urination, etc. It can be secondary to intestinal obstruction, intussusception, intestinal torsion, etc.. With the progress of the disease, it can be metastasized to lungs, bones, liver and other organs through blood line, causing corresponding symptoms. In addition, fibrosarcoma can secrete insulin-like substances, leading to hypoglycemia.
Examination
1. Physical examination
A mass can be palpated in the abdomen, which is hard in texture. If it invades the surrounding organs, the position is fixed.
2. CT)
Electron computed tomography (CT) examination shows a roundish solid abdominal mass with uneven density and irregular margins.
Diagnosis.
Clinical signs and symptoms of mesenteric fibrosarcoma are atypical. Imaging examination can clarify the morphology, location, size and relationship with surrounding tissues and organs, but often cannot determine the nature of the mass. Preoperative diagnosis is difficult, often need surgical exploration, tissue biopsy and pathological examination to confirm the diagnosis.
Treatment
Surgical treatment is preferred, and local wide excision is performed. Because fibrosarcoma is mostly hematogenous metastasis, lymphatic metastasis is rare, but the lymph node enlargement is still considered to be cleared. Postoperative radiation therapy has certain efficacy.